- Home
- TTNP vs LIXT Comparison
TTNP vs LIXT Comparison
Compare TTNP & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- LIXT
- Stock Information
- Founded
- TTNP 1991
- LIXT 2005
- Country
- TTNP United States
- LIXT United States
- Employees
- TTNP N/A
- LIXT N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- TTNP Health Care
- LIXT Health Care
- Exchange
- TTNP Nasdaq
- LIXT Nasdaq
- Market Cap
- TTNP 3.4M
- LIXT 4.1M
- IPO Year
- TTNP 1996
- LIXT N/A
- Fundamental
- Price
- TTNP $3.70
- LIXT $1.28
- Analyst Decision
- TTNP
- LIXT
- Analyst Count
- TTNP 0
- LIXT 0
- Target Price
- TTNP N/A
- LIXT N/A
- AVG Volume (30 Days)
- TTNP 9.7K
- LIXT 8.3K
- Earning Date
- TTNP 05-14-2025
- LIXT 05-08-2025
- Dividend Yield
- TTNP N/A
- LIXT N/A
- EPS Growth
- TTNP N/A
- LIXT N/A
- EPS
- TTNP N/A
- LIXT N/A
- Revenue
- TTNP N/A
- LIXT N/A
- Revenue This Year
- TTNP N/A
- LIXT N/A
- Revenue Next Year
- TTNP N/A
- LIXT N/A
- P/E Ratio
- TTNP N/A
- LIXT N/A
- Revenue Growth
- TTNP N/A
- LIXT N/A
- 52 Week Low
- TTNP $3.03
- LIXT $1.02
- 52 Week High
- TTNP $14.80
- LIXT $3.50
- Technical
- Relative Strength Index (RSI)
- TTNP 49.54
- LIXT 52.00
- Support Level
- TTNP $3.53
- LIXT $1.10
- Resistance Level
- TTNP $3.76
- LIXT $1.50
- Average True Range (ATR)
- TTNP 0.20
- LIXT 0.13
- MACD
- TTNP -0.00
- LIXT 0.02
- Stochastic Oscillator
- TTNP 32.79
- LIXT 45.00
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.